Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Authors: Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G. Henry, Jennifer C. Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V. Bondar, Rajarshi Ghosh, Michael T. Maloney, Nicholas E. Propson, Yuda Zhu, Romeo D. Maciuca, Laura Harris, Angela Kay, Peter LeWitt, T. Alex King, Drew Kern, Aaron Ellenbogen, Ira Goodman, Andrew Siderowf, Jason Aldred, Omid Omidvar, Shababa T. Masoud, Sonnet S. Davis, Annie Arguello, Anthony A. Estrada, Javier de Vicente, Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang Nguyen, Kimberly Scearce-Levie, Carole Ho, Matthew D. Troyer

Published: 2022-06-08

DOI: 10.1126/scitranslmed.abj2658

Source: Full article


Abstract

Mutations in leucine-rich repeat kinase 2 (